208 related articles for article (PubMed ID: 19995094)
21. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk.
Lacroix P; Crumb WJ; Durando L; Ciottoli GB
Eur J Pharmacol; 2003 Sep; 477(1):69-72. PubMed ID: 14512100
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of vardenafil and sildenafil on cardiac repolarization.
Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
[TBL] [Abstract][Full Text] [Related]
23. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M
Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879
[TBL] [Abstract][Full Text] [Related]
24. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
25. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
26. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
Shen Z; Gillen M; Tieu K; Nguyen M; Harmon E; Wilson DM; Kerr B; Lee CA
Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
[TBL] [Abstract][Full Text] [Related]
27. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.
Morganroth J; Gretler DD; Hollenbach SJ; Lambing JL; Sinha U
Expert Opin Pharmacother; 2013 Jan; 14(1):5-13. PubMed ID: 23216423
[TBL] [Abstract][Full Text] [Related]
28. Penetration of orally administered prulifloxacin into human lung tissue.
Concia E; Allegranzi B; Ciottoli GB; Orticelli G; Marchetti M; Dionisio P
Clin Pharmacokinet; 2005; 44(12):1287-94. PubMed ID: 16372826
[TBL] [Abstract][Full Text] [Related]
29. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization.
Litwin JS; Benedict MS; Thorn MD; Lawrence LE; Cammarata SK; Sun E
Antimicrob Agents Chemother; 2015; 59(6):3469-73. PubMed ID: 25845864
[TBL] [Abstract][Full Text] [Related]
30. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C
Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816
[TBL] [Abstract][Full Text] [Related]
31. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.
Mansbach RS; Ludington E; Rogowski R; Kittrelle JP; Jochelson P
Clin Ther; 2011 Jul; 33(7):851-62. PubMed ID: 21722958
[TBL] [Abstract][Full Text] [Related]
32. Effects of Celecoxib on the QTc Interval: A Thorough QT/QTc Study.
Kim S; Lee H; Ko JW; Kim JR
Clin Ther; 2019 Nov; 41(11):2204-2218. PubMed ID: 31564512
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
[TBL] [Abstract][Full Text] [Related]
34. A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects.
Linnebjerg H; Seger M; Kothare PA; Hunt T; Wolka AM; Mitchell MI
Int J Clin Pharmacol Ther; 2011 Oct; 49(10):594-604. PubMed ID: 21961484
[TBL] [Abstract][Full Text] [Related]
35. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Darpö B; Sager P; MacConell L; Cirincione B; Mitchell M; Han J; Huang W; Malloy J; Schulteis C; Shen L; Porter L
Br J Clin Pharmacol; 2013 Apr; 75(4):979-89. PubMed ID: 22882281
[TBL] [Abstract][Full Text] [Related]
36. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S
Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048
[TBL] [Abstract][Full Text] [Related]
37. Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.
Darpo B; Zhou M; Bai SA; Ferber G; Xiang Q; Finn A
Clin Ther; 2016 Feb; 38(2):315-26. PubMed ID: 26749217
[TBL] [Abstract][Full Text] [Related]
38. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
[TBL] [Abstract][Full Text] [Related]
39. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
Malik M; van Gelderen EM; Lee JH; Kowalski DL; Yen M; Goldwater R; Mujais SK; Schaddelee MP; de Koning P; Kaibara A; Moy SS; Keirns JJ
Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
[TBL] [Abstract][Full Text] [Related]
40. Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
Noel GJ; Natarajan J; Chien S; Hunt TL; Goodman DB; Abels R
Clin Pharmacol Ther; 2003 Apr; 73(4):292-303. PubMed ID: 12709719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
